Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Anti-estrogen-based endocrine therapies, such as the ER modulator Tamoxifen, ER degrader Fulvestrant, and the aromatase inhibitor Letrozole, have significantly enhanced the survival rates of patients with hormone receptor-positive (HR+) breast cancer [5]
Reviewed by Anne Schmidt This article was reviewed by Anne Schmidt
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
For example, cystine availability in cancers is limited that the TSS pathway is activated to provide an alternative source of cysteine 16
(4) Palindromic SNPs were removed
Baek KH, Ryeom S
US$ 21.35
US$ 27.19
US$ 29.70
US$ 29.90
US$ 25.20
